So sánh nối ruột đầu-cuối với phẫu thuật tạo hình hậu môn sau phẫu thuật cắt bỏ khối u thứ phát ở bệnh nhân ung thư buồng trứng biểu mô serous độ cao tái phát: Nghiên cứu quan sát tại một trung tâm

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424 Katić K, Matković V, Lešin et al (2019) First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab—our experience. Libri Oncol 47(2–3):64–70 Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59–78 Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85 Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493–498 Tseng JH et al (2016) Diverting ileostomy during primary debulking surgery for ovarian cancer: associated factors and postoperative outcomes. Gynecol Oncol 142(2):217–224 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259 Tozzi R et al (2018) Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 148(1):74–78 Kim M, Suh DH, Park JY et al (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60 Dood RL, Zhao Y, Armbruster SD et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519–1526 Bommert M, Harter P, Heitz F, du Bois A (2018) When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol) 30:493–497 Coleman RL, Spirtos NM, Enserro D et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381:1929–1939 Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 35:5501 (abstract) Armstrong DK et al (2019) National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer (version 2.2018). J Natl Compr Canc Netw 17(8):896-909. https://doi.org/10.6004/jnccn.2019.0039 Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539–543 National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in ovarian cancer. Version 1.2017 Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36–41 Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 20(12):3955–3960 Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36 da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 22:971–978 Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710 Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295 Richardson DL, Mariani A, Cliby WA (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2):667–672 Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126(2):220–223 Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608–614 Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül O et al (2021) European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer 31(9):1199–1206 Sier MF, van Gelder L, Ubbink DT, Bemelman WA, Oostenbroek RJ (2015) Factors affecting timing of closure and non-reversal of temporary ileostomies. Int J Color Dis 30(9):1185–1192 Waterland P, Goonetilleke K, Naumann DN, Sutcliff M, Soliman F (2015) Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies. J Clin Med Res 7(9):685–689 Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W et al (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123–2131